LONDON — ReNeuron (Guildford, UK) in early December submitted the further data requested in the investigational new drug file for its stem cell treatment for stroke, keeping it on track to be the first to carry out an FDA-approved trial of neural stem cells in a major neurological disorder. The file, originally submitted a year ago, was put on hold in January.